WASHINGTON — May 6, 2024 — DIA, a global organization of life sciences professionals, will showcase demonstrations from inventor Dean Kamen and his science and technology organizations during the DIA 2024 Global Annual Meeting from June 16-20 in San Diego.

Kamen's FIRST, Advanced Regenerative Manufacturing Institute (ARMI), and DEKA Research & Development Corporation will exhibit products and solutions alongside approximately 300 life science organizations during the world's preeminent multi-disciplinary life sciences forum.

Thousands of attendees will explore the latest healthcare innovations across 205,000 square feet of exhibition space, network with industry experts, and look into the future of their fields at the Global Annual Meeting, which will feature 220 sessions and more than 500 speakers.

 

"Our commitment to driving innovation and fostering collaboration in the life sciences will be on display in San Diego," said Marwan Fathallah, DIA's President and Global Chief Executive. "By bringing together the ingenuity of Dean Kamen and hundreds of other pioneers, we're helping redefine the boundaries of scientific possibility."

 

Kamen's organizations and collaborators will present more than a dozen innovations in medical and robotic technology, including:

—A decellularized porcine heart that has been injected with cultured human heart cells and can be used to create a bioartificial human heart for transplantation.

—A bone graft engineered from fat-derived stem cells and a decellularized bovine bone scaffold.

—A painless, self-administrable vaccine applicator for when the next pandemic strikes.

Kamen is one of three keynote speakers alongside Emily Whitehead, the first pediatric patient to undergo chimeric antigen receptor (CAR) T-cell therapy, and her father, Tom, who will share their patient perspectives.

Kamen will also join Peter Marks, MD, PhD, the Director of the Center for Biologics Evaluation and Research (CBER) at the FDA; Emer Cooke, MBA, MSc, the Executive Director of the European Medicines Agency (EMA); Stacy Hurt, MBA, MHA, the Chief Patient Officer of Parexel; David Mukanga, PhD, MPH, the Deputy Director of Africa Regulatory Systems at the Bill and Melinda Gates Foundation; and Carsten Linnemann, PhD, the co-founder and CEO of Neogene Therapeutics, a member of the AstraZeneca Group, for the opening plenary panel discussion.

Additionally, Linnemann will share insights on developing cell therapies for cancer patients and the value of collaboration in translating science to medicine.

Visit https://www.diaglobal.org/en/flagship/dia-2024 by May 15 to register before rates increase. Media members can request credentials by emailing diaglobal@gregoryfca.com.

 

Media Contact:
Denise DiMeglio
denise@gregoryfca.com
+1-610-228-2102